NR3C2 and hydrops fetalis: It is largely unknown whether SGLT2-I, RAAS inhibitors, mineralocorticoid receptor antagonists (MRA’s), beta-blockers, digitalis glycosides, and anti-inflammatory agents, which are the cornerstones of regular HF treatment, also address the metabolic abnormalities that drive cachexia.